Rheumatoid arthritis in the developing world

Best Practice and Research: Clinical Rheumatology

Volumn 17, Issue 5, 2003, Pages 863-875

  Kalla, Asgar Ali ^a   Tikly, Mohammed ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Biologicals; Developing countries; DMARD; Management; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GLUCOCORTICOID; GOLD SALT; HLA DR ANTIGEN; IMATINIB; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHENYTOIN; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; AURANOFIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

AFRICA; ALLERGIC PNEUMONITIS; ALOPECIA; BIOLOGICAL THERAPY; CATARACT; CLINICAL TRIAL; DEVELOPING COUNTRY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; DRUG TOXICITY; EPIDEMIOLOGICAL DATA; EYE TOXICITY; FINANCIAL MANAGEMENT; HEALTH SERVICE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; LIVER NECROSIS; LIVER TOXICITY; MEDICAL RESEARCH; NAUSEA AND VOMITING; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PHYSICAL DISABILITY; PREVALENCE; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOUTH AMERICA; SOUTHEAST ASIA; TRANSAMINITIS; TUBERCULOSIS; URBANIZATION; ABDOMINAL CRAMP; DISABILITY; DISEASE ACTIVITY; HEALTH CARE COST; HEMATOLOGIC DISEASE; INFECTION RISK; MONOTHERAPY; NAUSEA; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; PLASTIC SURGERY; VOMITING;

EID: 0042928285     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6942(03)00047-0     Document Type: Review

References (52)

1. Guidelines for the management of rheumatoid arthritis: 2002 update, American College of Rheumatology subcommittee on rheumatoid arthritis guidelines. Arthritis and Rheumatism 2002; 46: 328-346.
2. Silman AJ & Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Research 2002; 4(supplement 3): S265-S272.
3. Mody GM. Rheumatoid arthritis and connective tissue disorders: Sub-Saharan Africa. Baillière's Clinical Rheumatology 1995; 9: 31-44.
4. Silman AJ, Ollier W, Holligan S et al. Absence of rheumatoid arthritis in a Nigerian population. Journal of Rheumatology 1993; 20: 618-622.
5. Dans LF, Tankeh-Torres S, Amante CM & Penserga EG. The prevalence of rheumatic diseases in a Filipino urban population: A WHO-ILAR COPCORD Study. World Health Organisation. International League of Associations for Rheumatology. Community oriented programme for the control of the rheumatic diseases. Journal of Rheumatology 1997; 24: 1814-1819.
6. Hameed K, Gibson T, Kadir M et al. The prevalence of rheumatoid arthritis in affluent and poor urban communities of Pakistan. British Journal of Rheumatology 1995; 34: 252-256.
7. Mody GM & Meyers OL. Rheumatoid arthritis in blacks in South Africa. Annals of the Rheumatic Diseases 1989; 48: 69-72.
8. Darmawan J, Muirden KD, Valkenburg HA & Wigley RD. The epidemiology of rheumatoid arthritis in Indonesia. British Journal of Rheumatology 1993; 32: 537-540.
9. Mijiyawa M. Epidemiology and semiology of rheumatoid arthritis in Third World Countries. Review Rheumatologica (English Edition) 1995; 62: 121-126.
10. Palmer Beasley R, Bennett PH & Lin CC. Low prevalence of rheumatoid arthritis in Chinese. Journal of Rheumatology 1983; 10(supplement 10): 11-15.
11. Kaliski S, Bustos L, Alarcon C et al. Rheumatoid arthritis among Mapuche Aborigines. A 16 years experiment in the IX region of the Chile. Review of Medicine in Chile 2001; 29: 253-258.
12. Spindler A, Bellomio V, Berman A et al. Prevalence of rheumatoid arthritis in Tucuman, Argentina. Journal of Rheumatology 2002; 29: 1166-1170.
13. Zeng Q, Huang S & Chen R. 10-Year epidemiological study on rheumatic diseases in Shantou area. Zhongkua Nei Ke Za Zhi 1997; 36: 193-197.
14. Beighton P, Solomon L & Valkenburg HA. Rheumatoid arthritis in a rural South African Negro population. Annals of the Rheumatic Diseases 1975; 34: 136-141.
15. Abdel-Nassar AM, Rasker JJ & Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Seminars in Arthritis and Rheumatism 1997; 27: 123-140.
16. Kalla AA, Smith PR, Brown GMM et al. Responsiveness of Keitel functional index compared with laboratory measures of disease activity in rheumatoid arthritis. British Journal of Rheumatology 1995; 34: 141-149.
17. Tikly M, Zannettou N & Hopley M. A longitudinal study of rheumatoid arthritis in South Africans. Medscape General Medicine 2003: 5 http://www.medscape.com/viewarticle/448141
18. Mody GM, Shaw J & Ramchurren A. Rheumatoid arthritis impact survey. South African Medical Journal 1988; 74: 409-410.
19. Martell RW, Du Toit ED, Kalla AA & Meyers OL. Association of rheumatoid arthritis with HLA in three South African populations - Whites, Blacks and a population of mixed ancestry. South African Medical Journal 1989; 76: 189-190.
20. Mody GM, Hammond MG & Naidoo PD. HLA association with rheumatoid arthritis in African blacks. Journal of Rheumatology 1989; 16: 1326-1328.
21. Pile KD, Tikly M, Bell JI & Wordsworth BP. HLA-DR antigens and rheumatoid arthritis in Blacks: A study of ethnic groups. Tissue Antigens 1992; 39: 138-140.
22. Mody GM & Meyers OL. Resorptive arthropathy in rheumatoid arthritis. Journal of Rheumatology 1988; 15: 1075-1077.
23. Mody GM & Meyers OL. A radiographic survey of hip involvement in rheumatoid arthritis. Scandinavian Journal of Rheumatology 1988; 17: 223-224.
24. Adebajo AO & Reid DM. The pattern of rheumatoid arthritis in West Africa and comparison with a cohort of British patients. Quarterly Journal of Medicine 1991; 80: 633-640.
25. Glave-Testino C, Cardiel MH, Arce-Salinas A & Alarcon-Segovia D. Factors associated with disease severity in Mexican patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 1994; 12: 589-594.
26. Veerapen K, Mangat G & Dieppe P. The expression of rheumatoid arthritis in Malaysian and British patients: A comparative study. British Journal of Rheumatology 1993; 32: 541-545.
27. Van Doornum S, McColl G & Wicks IP. Accelerated atherosclerosis: An extra-articular feature of rheumatoid arthritis? Arthritis and Rheumatism 2002; 46: 862-873.
28. Pincus T, Ferraccioli G, Sokka T et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: Updating a 1983 review. Rheumatology 2002; 41: 1346-1356.
29. Kremer JM, Alarcon GS, Lightfoot Jr. RW et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis and Rheumatism 1994; 37: 316-328.
30. Yazici Y, Erkan D & Paget SA. Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: Is it time to update the guidelines? Journal of Rheumatology 2002; 29: 1586-1588.
31. Scholtz CL, Odendaal HJ, Thiart R et al. Analysis of two mutations in the MTHFR gene associated with mild hypercysteinaemia - Heterogeneous distribution in the South African population. South African Medical Journal 2002; 92: 462-467.
32. Cohen S, Cannon GW, Schiff M et al. Two-year, blinded, randomised, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Investigator Group. Arthritis and Rheumatism 2001; 44: 1984-1992.
33. Kremer JM. Not yet time to change the guidelines for monitoring methotrexate liver toxicity: They have served us well. Journal of Rheumatology 2002; 29: 1590-1592.
34. Ito S, Nakazono K, Murasawa A et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patients. Arthritis and Rheumatism 2001; 44: 339-342.
35. Olsen NJ, Callahann LF & Pincus T. Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis and Rheumatism 1987; 30: 481-488.
36. Aletaha D & Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. Journal of Rheumatology 2002; 29: 1631-1638.
37. Furst DE, Lindsley H, Baethge B et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with eighteen-week extension. Arthritis and Rheumatism 1999; 42: 357-365.
38. Paton NI, Aboulhab J & Karim F. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. The Lancet 2002; 359: 1667-1668.
39. O'Dell JR, Leff R, Paulsen G et al. Treatment of rheumatoid arthritis with methotrexate and hydrochloroquine, methotrexate and sulfasalazine, or a combination of the three medications: Results of a two-year, randomised, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2002; 46: 1164-1170.
40. Moreland LW & O'Dell JR. Glucocorticoids and rheumatoid arthritis: Back to the future? Arthritis and Rheumatism 2002; 46: 2553-2563.
41. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. The Lancet 1997; 350: 309-318.
42. Farooqi AZ, Aman NR, Qamar R & Aziz S. Glucocorticoid use and abuse by medical practitioners for arthritis and related disorders in Pakistan. British Journal of Rheumatology 1997; 36: 91-94.
43. Bileckot R & Malonga AC. Rheumatoid arthritis in Congo-Brazzaville. A study of thirty-six cases. Review Rheumatologica (English Edition) 1998; 65: 308-312.
44. Gaitonde S, Pathan E, Sule A et al. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Annals of the Rheumatic Diseases 2002; 61: 251-253.
45. Sambrook PN. The skeleton in rheumatoid arthritis: Common mechanisms for bone erosion and osteoporosis? Journal of Rheumatology 2000; 27: 2541-2542.
46. Ramsey-Goldman R. Missed opportunities in physician management of glucocorticoid-induced osteoporosis? Arthritis and Rheumatism 2002; 46: 3115-3120.
47. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. New England Journal of Medicine 1995; 333: 137-141.
48. Gutierrez-Rodriguez O, Starusta-Bacal P & Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis - The thalidomide experience. Journal of Rheumatology 1989; 16: 158-163.
49. Rao URK, Naidu MUR, Kumar TR et al. Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis - A double blind study. Journal of Rheumatology 1995; 22: 1235-1240.
50. O'Dell JR, Paulsen G, Haire CE et al. Treatment of early seropositive rheumatoid arthritis with minocycline: Four-year follow-up of a double blind, placebo-controlled trial. Arthritis and Rheumatism 1999; 42: 1691-1695.
51. Mayordomo L, Marenco JL, Gomez-Mateos J & Rejon E. Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scandinavian Journal of Rheumatology 2002; 31: 44-45.
52. Furst DE, Cush J & Kaufmann S. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Annals of the Rheumatic Diseases 2002; 61 (supplement II): ii62-ii63.